Acute effects of a beverage containing bitter melon extract (CARELA) on postprandial glycemia among prediabetic adults

CH Boone1, JR Stout1, JA Gordon1, MJ Redd1, DD Church1, LP Oliveira1,2, DH Fukuda1 and JR Hoffman1

INTRODUCTION

Momordica charantia, also known as bitter melon (BM), has been purported to have an antihyperglycemic effect, which may serve as a treatment option for managing diabetes mellitus.1–4 Further, the ingestion of BM has been shown to elicit an acute hypoglycemic effect5–8 and improve the postprandial glycemic response during oral glucose tolerance testing among diabetics.6,9,10 Conversely, others have reported no significant reduction in postprandial blood glucose concentrations during glucose tolerance testing among non-diabetics,11,12 highlighting the notion that one’s ability to maintain blood glucose homeostasis may determine the efficacy of BM. In support, previous studies have shown the presence of responders and non-responders to BM ingestion.9,11,13

Although there have been a number of studies examining the antidiabetic properties of BM in both animals and humans, minimal research has examined these effects with regard to prediabetics. In fact, evidence of the effects of BM on glucose regulation in prediabetics has merely been inferred from studies among diabetics.14 Individuals with prediabetes suffer from moderate glucose dysregulation via impaired glucose tolerance and/or impaired fasting glucose15 and are at risk for developing type 2 diabetes mellitus if left untreated.16 Moreover, persistently elevated blood glucose levels are associated with many other comorbidities, such as kidney disease, neuropathies and macrovascular complications.16 Nevertheless, it is possible for one to convert to a healthy, normoglycemic state through certain lifestyle, pharmacological and/or nutritional interventions14,16, thus the ingestion of an antihyperglycemic agent such as BM may help to minimize the risk of disease progression. Therefore, the purpose of this investigation was to examine the efficacy of BM extract to aid blood glucose regulation in a group of prediabetic adults.

MATERIALS AND METHODS

Subjects

Ten prediabetic adults with fasting plasma glucose concentrations between 99 and 126 mg dl−1 and/or hemoglobin A1c level between 5.7% and 6.4% volunteered to participate in this single-blinded, cross-over design investigation. Prior to data collection, all subjects completed confidential health questionnaires to assess health status and possible risk factors. Additionally, all subjects provided written consent prior to any data collection. Subjects were asked to avoid participation in any other clinical/investigational trials throughout the duration of this experiment. The New England Independent Review Board’s approval was obtained prior to data collection.
Experimental trials
All subjects were asked to visit the University’s Human Performance Laboratory on three separate occasions. During the first visit (D1), laboratory staff provided a thorough explanation of all procedures, expectations and potential risks of study participation; determined subject eligibility; and assessed body composition via air displacement plethysmography (BodPod, COSMED, Chicago, IL, USA). On the second visit (D2), subjects reported to the laboratory following an 8–10-h fast and underwent an oral glucose tolerance test (OGTT). Following a minimum of 96 h, subjects reported to the laboratory (D3) following an 8–10-h fast and underwent an additional OGTT. During D3, subjects consumed a beverage containing 1.25–3 g of BM extract 30 min prior to the OGTT.

During each experimental trial, subjects were asked to ingest a 75-g glucose beverage (SUN-DEX, Fisher Healthcare, Houston, TX, USA) within a 5-min period. For the duration of the standard 2-h OGTT, blood samples were collected every 30 min.

Blood measurements
During each experimental trial, blood samples were collected at six time points. During D2, blood samples were collected upon arrival (BL), after 30 min, another sample was taken immediately prior to glucose intake (PRE), then again 30, 60, 90 and 120 min after glucose intake (30P, 60P, 90P and 120P, respectively). During D3, the BM beverage was consumed promptly after the BL blood draw; and all subsequent blood draws followed the same protocol as D2. In between blood draws, participants remained inactive (that is, seated or lying down) in the Human Performance Laboratory. All blood draws were obtained following a 15-min equilibration period wherein subjects were instructed to lie in a supine position. All blood samples were obtained using a Teflon cannula placed in a superficial forearm vein using a three-way stopcock with a male luer-lock adapter and plastic syringe. The cannula was maintained patent using an isotonic saline solution (Becton, Dickinson and Co., Franklin Lakes, NJ, USA).

At each time point, blood samples were collected into two 6 ml Vacutainer tubes—one untreated and the other coated with K$_2$EDTA (Becton Dickinson and Co., Franklin Lakes, NJ). Samples were subsequently centrifuged at 3000 r.p.m. for 15 min at 4 °C. The resulting supernatants were aliquoted into separate micro-centrifuge tubes and frozen at −80 °C for later analyses.

Biochemical analyses
Plasma glucose was assessed using the glucose oxidase method via an automated analyzer (Analox GM7, Analox Instruments Ltd., Lunenburg, MA, USA). Serum insulin concentrations were determined via commercially available enzyme-linked immunosorbent assay kits (IS130D; Calbiotech, Inc., Spring Valley, CA, USA) and a spectrophotometer (Eon, BioTek Instruments, Inc., Winooski, VT, USA). Following analyses, total area under the glucose and insulin curves (AUC$_{\text{glu}}$ and AUC$_{\text{ins}}$, respectively) were calculated using a standard trapezoidal method. To eliminate interassay variance, all samples were analyzed in duplicate by a single technician. The coefficient of variation for each assay was 0.87% for glucose and 8.24% for insulin.

Grouping
Subjects were grouped according to their distinct response to the initial OGTT based on previously published methods; subjects categorized by their postprandial glucose response pattern—Fastpeak (peak glucose concentration observed at 30P) and Slowpeak (peak glucose concentration observed after 30P).

Statistical analyses
All participants. Acute effects of the study beverage on biochemical measures among all prediabetic subjects were analyzed using separate two-way, repeated-measures (trial (D2 vs D3) × time (BL vs PRE vs 30P vs 60P vs 90P vs 120P)) analyses of variance (ANOVCAs).

Responders. Previous research suggests that BM may lower postprandial glucose in a portion of its consumers. Therefore, further analyses examined the effects of the study beverage among subjects who were determined to be responders—defined as individuals whose total AUC$_{\text{glu}}$ during D3 was lower than D2. Separate three-way, repeated-measures (group (responders vs non-responders) × trial (D2 vs D3) × time (BL vs PRE vs 30P vs 60P vs 90P vs 120P)) ANOVAs were used to assess the acute effects of the study beverage on the postprandial glucose and insulin responses among responders.

RESULTS
Subject characteristics are displayed in Table 1. Percentage of body fat and body mass index were not significantly different between Fastpeak and Slowpeak ($P = 0.416$ and $P = 0.437$, respectively), but Fastpeak tended to be younger than Slowpeak ($95\%$ CI: 66.9–66.9 vs 57.7–72.8; $P = 0.093$). When comparing responders and non-responders, no significant differences were noted for percentage of body fat ($P = 0.491$), body mass index ($P = 0.948$) or age ($P = 0.143$).

Changes in the postprandial glycemic response
Glycemic responses during each experimental trial are displayed in Table 2. When assessing all subjects, no significant trial × time interaction was observed for plasma glucose concentrations ($P = 0.732$), but significant time effects were noted ($P < 0.001$). Plasma glucose was significantly elevated from BL (95% CI: 100.0–115.1) at 30P (95% CI: 143.9–174.5; $P < 0.001$), 60P (95% CI: 119.6–174.5; $P = 0.005$) and 90P (95% CI: 110.6–161.8; $P = 0.023$). No significant between-trial differences were observed for AUC$_{\text{glu}}$ ($P = 0.723$), mean plasma glucose (Glumean; $P = 0.720$) or peak plasma glucose (Glumean; $P = 0.399$).

When assessing the effects of the BM beverage among responders ($n = 5$) and non-responders ($n = 5$), a significant group × trial × time interaction was observed for plasma glucose concentrations ($P = 0.008$; Figure 1). A significant trial × time interaction was observed for responders ($P = 0.004$) but not for

### Table 1. Baseline characteristics of prediabetic subjects

|                     | Total (n = 10) | Fastpeak (n = 5) | Slowpeak (n = 5) | Responders (n = 5) | Non-responders (n = 5) |
|---------------------|---------------|-----------------|-----------------|-------------------|-----------------------|
| Gender (M/F)        | 4/6           | 2/3             | 2/3             | 2/3               | 2/3                   |
| Age (years)         | 60.8 (8.5)    | 56.3 (8.6)      | 65.2 (6.1)      | 64.7 (6.5)        | 56.8 (8.9)            |
| Body fat (%)        | 33.1 (12.8)   | 29.6 (11.3)     | 36.6 (14.5)     | 36.1 (14.0)       | 30.1 (12.3)           |
| BMI (kg m$^{-2}$)   | 26.2 (5.5)    | 24.8 (5.2)      | 27.7 (6.1)      | 26.4 (4.4)        | 26.1 (7.1)            |

Abbreviations: BMI, body mass index; F, female; M, male. Data are reported as mean (s.d.).
Changes in the postprandial insulin response
When assessing all subjects, no significant trial × time interaction was observed for serum insulin concentrations (P = 0.307), but significant time effects were noted (P = 0.033). Serum insulin was significantly elevated from BL (95% CI: 0.5–3.1) at 30P (95% CI: 7.4–75.0; P = 0.025), 60P (95% CI: 1.7–100.2; P = 0.048), 90P (95% CI: 5.5–80.2; P = 0.032) and 120P (95% CI: 7.9–53.7; P = 0.017). No significant between-trial differences were observed for total AUCins (P = 0.836), Insmean (P = 0.839) or Inspeak (P = 0.126).

When assessing the effects of the BM beverage among responders (n = 5) and non-responders (n = 5), no significant group × trial × time interaction was observed for serum insulin concentrations (P = 0.276). Similarly, no significant trial × time interaction was observed for responders (P = 0.260) or non-responders (P = 0.695). Additionally, no significant group × time interactions were noted during either trial (D2: P = 0.177; D3: P = 0.487); but significant time effects were observed

### Table 2. Differences in the glycemic response during an oral glucose tolerance test with (D3) and without (D2) acute bitter melon extract ingestion

|                          | D2                | D3                |
|--------------------------|-------------------|-------------------|
|                          | Total (n = 10)    | Responders (n = 5) | Non-responders (n = 5) |
| BL                       | 108.2 (11.1)      | 114.0 (6.7)       | 102.4 (12.2)           |
| PRE                      | 106.6 (11.0)      | 112.3 (6.9)       | 101.0 (10.1)           |
| 30P                      | 158.4 (23.8)      | 162.7 (33.9)      | 154.2 (8.7)            |
| 60P                      | 151.0 (40.0)      | 161.9 (51.7)      | 140.0 (25.1)           |
| 90P                      | 137.8 (33.0)      | 147.0 (27.0)      | 128.7 (38.9)           |
| 120P                     | 116.7 (21.9)      | 121.0 (16.6)      | 112.4 (27.5)           |

Abbreviations: BL, blood samples collected upon arrival; PRE, blood samples taken immediately prior to glucose intake. 30P, 60P, 90P and 120P, blood samples taken 30, 60, 90 and 120 min after glucose intake, respectively. Data are reported as mean mg dl⁻¹ (s.d.).
BM has been previously shown to enhance glucose tolerance in diabetics during an OGTT following a single-dose treatment. However, a number of the investigations demonstrating the efficacy of BM as a hypoglycemic agent have acknowledged the presence of responders and non-responders. In this sample of prediabetics, 50% of all subjects experienced a significant improvement in their glycemic response to the OGTT following an acute ingestion of the study beverage. This is evidenced by the reduced total AUCgly (−13.2% ± 3.9%) and mean glucose concentration (−12.2% ± 4.1%) compared with the control trial (D2). Acute ingestion of the study beverage 30 min prior to the OGTT also attenuated the postprandial increase in blood glucose during D3 compared with D2, indicated by a reduced Glupeak Concentration (−10.6% ± 5.6%) and lower concentrations at 30P (−9.1% ± 5.2%), 60P (−24.0% ± 10.3%) and 90P (−20.0% ± 12.7%). Similarly, Leatherdale et al. observed significant reductions in plasma glucose concentrations and incremental AUCgly among non-insulin-dependent, type 2 diabetics during the initial 90 min of a 120-min OGTT when 50 ml of BM was consumed. Furthermore, others have reported an improved postprandial glycemic response—that is, lowered blood glucose levels—among type 2 diabetics when 100 ml of BM was consumed at least 30 min prior to glucose administration.

In contrast, some studies have reported no significant impact of BM on blood glucose concentrations during OGTT. Specifically, Kasbia et al. observed no significant improvement in the glycemic response during an OGTT when non-diabetic, overweight men consumed 100 mg kg<sup>−1</sup> of BM juice. In addition, no improvement in plasma glucose levels were reported in healthy rats consuming 0.6 g kg<sup>−1</sup> of BM extract during an OGTT. Furthermore, ingestion of 100 ml of BM juice did not improve the glycemic response to a glucose load among insulin-dependent diabetic rats. Although these opposing conclusions may be due to different forms, dosage and/or preparation of the BM (for example, juice or extract), the inconsistent results may also highlight the individual nature of glucose metabolism. In the present study, subjects displayed two distinct response patterns to the OGTT—those whose highest glucose concentration was observed 30 min after glucose ingestion and those whose highest glucose concentration was observed sometime after the 30-min mark. As the shape of the glucose curve during glucose testing has been suggested to provide metabolic information regarding one’s level of glucose tolerance, where greater complexity of the response curve is associated with improved glucose tolerance, this sample appears to represent individuals with slightly impaired Fastpeak and more extensively impaired Slowpeak metabolic condition. Although we were able to classify metabolic responses as Fastpeak and Slowpeak, neither group experienced a significant change in the postprandial glycemic response during an OGTT when the study beverage was consumed 30 min prior to glucose ingestion in the present study.

While some hypothesize that BM acts as an insulin secretagogue in vivo thereby enhancing glucose disposal, others posit that its hypoglycemic effects are due to enhancement of glucose metabolism, augmenting tissue sensitivity to glucose and/or inducing translocation of glucose transporter isoform 4 (GLUT4). In addition, BM may also inhibit α-glucosidase activity within the small intestine, thus reducing glucose digestion and absorption along the alimentary canal. Moreover, a primary chemical constituent of BM, polypeptide-p, has demonstrated insulin-mimetic hypoglycemic properties. Previous research has shown an acute hypoglycemic effect of BM ingestion with and without an amplified insulin response, suggesting that the efficacy of BM may be due to the combined effect of multiple mechanisms. In the present study, BM failed to produce a significant insulinogenic effect suggesting that the acute improvement in glucose tolerance may be attributable to extra-pancreatic mechanisms such as increased GLUT4 activity or...
enhanced glucose uptake in the skeletal muscle and liver. As the aforementioned explanations were beyond the scope of this investigation, future research may consider examining the acute effects of BM ingestion on a molecular level to assess its efficacy with regard to subclinical, prediabetic individuals.

CONCLUSION

The present results suggest that the acute ingestion of a beverage containing BM extract may promote an improvement in glucose tolerance during an OGTT among some individuals with impaired glucose regulation. Similar to previous findings, the observed reduction in postprandial glycemia occurred independently of an altered insulin response. Further research is needed to fully elucidate the effects of BM on glucose regulation in prediabetic adults.

CONFLICT OF INTEREST

We thank CARELA, Inc. for generously providing the beverage used in this investigation, as well as Alyssa N Varanoske and Sarah J Dodd for their assistance during data collection.

ACKNOWLEDGEMENTS

We thank CARELA, Inc. for generously providing the beverage used in this investigation, as well as Alyssa N Varanoske and Sarah J Dodd for their assistance during data collection.

REFERENCES

1. Joseph B, Jini D. Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pac J Trop Dis 2013; 3: 93–102.
2. Paul A, Raychaudhuri SS. Medicinal uses and molecular identification of two Momordica charantia varieties-a review. Electron J Biol 2010; 6: 43–51.
3. Tan SP, Kha TC, Parks SE, Roach PD. Bitter melon (Momordica charantia L) bioactive composition and health benefits: a review. Food Rev Int 2016; 32: 181–202.
4. Yin R, Lee N, Hirpara H, Phung O. The effect of bitter melon (Momordica charantia) in patients with diabetes mellitus: a systematic review and meta-analysis. Nutr Diabetes 2014; 4: e145.
5. Baldova V, Bhandari C, Pangaria A, Goyal R. Clinical trial in patients with diabetes mellitus of an insulin-like compound obtained from plant source. Ups J Med Sci 1977; 82: 39–41.
6. Leatherdale B, Panesar R, Singh G, Atkins T, Bailey C, Bignell A. Improvement in glucose tolerance due to Momordica charantia (karela). Br Med J (Clin Res Ed) 1981; 282: 1823–1824.
7. Srivastava Y, Venkatakrishna-Bhatt H, Verma Y, Venkaiah K, Raval B. Antidiabetic and adaptogenic properties of Momordica charantia extract: an experimental and clinical evaluation. Phytother Res 1993; 7: 285–289.
8. Yeh GY, Eisenberg DM, Kapchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003; 26: 1277–1294.
9. Ahmad N, Hassan M, Halder H, Bennoor K. Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. Bangladesh Med Res Counc Bull 1999; 25: 11–13.
10. Welhinda J, Karunanyake E, Sheriff M, Jayasinghe K. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J Ethnopharmacol 1986; 17: 277–282.
11. Kasbia GS, Arnason JT, Imbeault P. No effect of acute, single dose oral administration of Momordica charantia Linn., on glycemia, energy expenditure and appetite: a pilot study in non-diabetic overweight men. J Ethnopharmacol 2009; 126: 127–133.
12. Uebanso T, Arai H, Taketani Y, Fukaya M, Yamamoto H, Mizuno A et al. Extracts of Momordica charantia suppress posthyperglycemia in rats. J Nutr Sci Vitaminol 2007; 53: 482–488.
13. Thungantr K, Pusonathornthum P, Fish K, Yibchok-anun S. Treatment of canine diabetes mellitus using Momordica charantia capsule and a restricted-fat high-fiber diet. J Med Plant Res 2010; 4: 2243–2251.
14. Efird JT, Choi YM, Davies SW, Mehra S, Anderson EJ, Katunga LA. Potential for improved glycemic control with dietary Momordica charantia in patients with insulin resistance and pre-diabetes. Int J Environ Res Public Health 2011; 14: 2328–2345.
15. Wang G, Liu X, Christoffel KK, Zhang S, Wang B, Liu R et al. Prediabetes is not all about obesity: association between plasma leptin and prediabetes in lean rural Chinese adults. Eur J Endocrinol 2010; 163: 243–249.
16. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet 2012; 379: 2279–2290.
17. Csato T. Atypical responses to the glucose tolerance test in normal subjects. Int J Biometeorol 1966; 12: 369–376.
18. Tschirner O, Fritsche A, Shirkavand F, Machicao F, Häring H, Stumvoll M. Assessing the shape of the glucose curve during an oral glucose tolerance test. Diabetes Care 2003; 26: 1026–1033.
19. Ali L, Khan AKA, Mamun MIR, Moshiuzzaman M, Nahar N, Nur-E-alam M et al. Studies on hypoglycemic effects of fruit pulp, seed, and whole plant of Momordica charantia on normal and diabetic model rats. Planta Med 1993; 59: 408–412.
20. Morris C, O’Grada C, Ryan M, Roche HM, Gibney MJ, Gibney ER et al. Identification of differential responses to an oral glucose tolerance test in healthy adults. PLoS One 2013; 8: e72890.
21. Tura A, Morbiducci U, Sbrignadello S, Winhofer Y, Pacini G, Kautzky-Willer A. Shape of glucose, insulin, C-peptide curves during a 3-h oral glucose tolerance test: any relationship with the degree of glucose tolerance? Am J Physiol Regul Integr Comp Physiol 2011; 300: R941–R948.
22. Yibchok-Anun S, Adisakwattana S, Yao CY, Sangvanich P, Rongsumran S, Hsu WH. Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulomimetic activities. Biol Pharm Bull 2006; 29: 1126–1131.
23. Chaturvedi P. Antidiabetic potentials of Momordica charantia: multiple mechanisms behind the effects. J Med Food 2012; 15: 101–107.
24. Tan M-J, Ye J-M, Turner N, Hohnen-Behrens C, Ke C-Q, Tang C-P et al. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol 2008; 15: 263–273.
25. Day C, Cartwright T, Provost J, Bailey C. Hypoglycaemic effect of Momordica charantia extracts. Planta Med 1990; 56: 426–429.
26. Sarkar S, Pranava M, Marita AR. Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes. Pharmacol Res 1996; 33: 1–4.

Nutrition & Diabetes (2017) 1 – 5

Acute effects of bitter melon ingestion
CH Boone et al

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017